Study ID | Phase | Study Subjects | Inference |
---|---|---|---|
Trier et al. 1 | Clinical Phase II | (36‑month pilot study) 68 myopic children (mean age: 11.3 years) | ND-10 was found to be effective. |
Study ID | Phase | Animals used | Inference |
---|---|---|---|
Trier et al. 2 | Preclinical | 6 pigmented rabbits (age: 8 weeks) | ND-10 was found to be effective. |
Cui et al. 3 | Preclinical | 7 guinea pigs (age: 3 weeks) | ND-10 was found to be effective. |
Nie et al. 4 | Preclinical | 8 pigmented rabbits (age: 10 days) | ND-10 was found to be effective. |
Hung et al 5 | Preclinical | 16 rhesus monkeys (age: 2-3 weeks) | ND-10 was found to be effective. |
Theialife’s new molecule is a first in class, novel, oral therapy in the treatment and management of Myopia in children. This first in class molecule will change the Myopia management landscape, especially for children with early-onset Myopia, who otherwise, given the limited therapies available, are bound to progress towards severe and sight threatening Myopia.
ND-10 competitively blocks adenosine receptors. These receptors modulate various retinal neurotransmitters believed to control eye growth. ND 10 increases the collagen concentration and collagen fibril diameter in the posterior sclera and thereby inhibits eye elongation and Myopia progression in animals subjected to form-deprivation or lens induced Myopia.